AUGUST 2025

Date	Headline and Source	Link	Summary
5th August	Eli Lilly opens tech, innovation centre in Hyd with plans to hire 1,500 in 2-3 yrs The Times of India, August 05, 2025	Eli Lilly opens tech, innovation centre in Hyd with plans to hire 1,500 in 23 yrs	Pharma giant Eli Lilly and Company (India) opened its new technology and innovation centre in Hyderabad's Hitech City, spanning 2 2 lakh sq ft. The global capability centre (GCC) already houses around 100120 employees and plans to accommodate around 1,500 employees by 2026-27.
5th August	CM inaugurates U.S. major Eli Lilly's GCC in Hyderabad The Hindu, August 05, 2025	CM inaugurates U.S. major Eli Lilly's GCC in Hyderabad	Chief Minister A. Revanth Reddy inaugurated US pharma major Eli Lilly's Global Capability Centre in Hyderabad on Monday. After the launch, the Chief Minister described it as a clinching proof that in less than 20 months, with IT & Industries Minister D. Sridhar Babu's vision and hard work, the government made Hyderabad the Global GCC capital and hub.
7th August	AstraZeneca to launch eculizumab in India this August for rare blood disorders CNBC TV18, August 07, 2025	AstraZeneca to launch eculizumab in India this August for rare blood disorders	Earlier this year in January, AstraZeneca received regulatory clearance from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute the drug across India. The approval was granted in Form CT20 by the Drugs Controller General of India, officially allowing the sale of Eculizumab concentrate for infusion 300 mg (10mg/ml).
10th August	Eli Lilly Gets CDSCO Panel Nod for Ixekizumab Safety Label Update Medical Dialogues, August 10, 2025	Eli Lilly Gets CDSCO Panel Nod for Ixekizumab Safety Label Update	Eli Lilly and Company (India) Pvt Ltd has secured regulatory clearance from the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) for updating the package insert of its drug Ixekizumab Solution for Injection 80 mg/mL, in both pre-filled autoinjector and pre-filled syringe formats.
11th August	CDSCO Panel Recommends Approval For Vorasidenib With Phase-III Waiver, Mandates Phase-IV Trial In India Medical Dialouges, August 11, 2025	CDSCO Panel Recommends Approval For Vorasidenib With Phase-III Waiver, Mandates Phase-IV Trial In India	The proposal was reviewed during the SEC meeting held on 17th July 2025, where the company sought approval for the drug along with exemption from conducting local Phase-III clinical trials. The committee noted that Vorasidenib has already been granted orphan drug status in other countries, and that the prescribing information for the Indian product was in line with regulatory approvals abroad.

12th August	Roche Gets Nod to Import, Sell Cancer Drug in India The Economic Times, August 12, 2025	Roche Gets Nod to Import, Sell Cancer Drug in India	Roche has received approval from the technical committee for supervising clinical trials on new chemical entities, to import and market cancer drug Atezolizumab injection (Tecentriq) in India. Teena Thacker reports.
12th August	Roche Gets Nod to Import, Sell Cancer Drug in India The Economic Times, August 12, 2025	Roche Gets Nod to Import, Sell Cancer Drug in India	Roche has received approval from the technical committee for supervising clinical trials on new chemical entities, to import and market cancer drug Atezolizumab injection (Tecentriq) in India. Teena Thacker reports.
13th August	Pneumococcal Conjugate vaccine for adults launched in India by Pfizer Express Healthcare, August 13, 2025	Pneumococcal Conjugate vaccine for adults launched in India by Pfizer	Pfizer has announced the launch of its 20valent pneumococcal conjugate vaccine (PCV20) for adults in India. The vaccine offers protection against invasive and non-invasive pneumococcal disease caused by 20 Streptococcus pneumoniae (pneumococcus) serotypes.
14th August	Government of Goa to implement pricing policy for innovative lifesaving therapies BioSpectrum India, August 14, 2025	Government of Goa to implement pricing policy for innovative lifesaving therapies	Proposed by Organisation of Pharmaceutical Producers of India (OPPI), an independent body representing research based global pharmaceutical companies in India, this critical policy is expected to strengthen Goa's preparedness for future health challenges and ensure long-term resilience by integrating affordability, innovation, and public health priorities.
14th August	Pfizer launches new single-shot pneumococcal vaccine in India - Are you in the high-risk group? The Financial Express, August 14, 2025	Pfizer launches new single-shot pneumococcal vaccine in India - Are you in the high-risk group?	Pfizer has introduced a new 20valent pneumococcal conjugate vaccine (PCV20) in India to protect adults from 20 different types of Streptococcus pneumoniae. The vaccine is approved for anyone aged 18 and above and is safer than any previous pneumococcal vaccine in the country.
14th August	Eli Lilly launches Mounjaro pen in India as obesity drug race heats up Live Mint, August 14, 2025	Eli Lilly launches Mounjaro pen in India as obesity drug race heats up	Eli Lilly has stepped up its fight with Novo Nordisk in India's fast-growing anti-obesity market, launching a prefilled pen version of its blockbuster weight-loss drug Mounjaro at the same price as its injectable vials. The KwikPen, available in six dosage strengths, follows the March launch of Mounjaro in injectable vials, giving Lilly an early-mover advantage in India.
17th August	Goa govt expands AI-powered lung cancer screening with Qure.ai & AstraZeneca, launches pricing policy for	Goa govt expands AI-powered lung cancer screening with Qure.ai & AstraZeneca,	Thats in the state sustainable, backed by a predictable and collaborative procurement pathway. Proposed by Organisation of Pharmaceutical Producers

	lifesaving therapies Bio Voice News, August 17, 2025	launches pricing policy for lifesaving therapies	of India (OPPI), an independent body representing research based global pharmaceutical companies in India, this critical policy is expected to strengthen Goa's preparedness for future health challenges and ensure long-term resilience by integrating affordability, innovation, and public health priorities.
21st August	Four new drugs for rare diseases on anvil; five medications for 7 ailments in market: VK Paul The Economic Times, August 21, 2025	Four new drugs for rare diseases on anvil; five medications for 7 ailments in market: VK Paul	He noted that the government aims to treat rare diseases and orphan drugs as a strategic priority area among the priority areas with higher policy support. Novartis MD & Country President Amitabh Dube said rare diseases affect over 300 million globally, with 7090 million in India.
24th August	Takeda eyes India for global clinical trials amid booming clinical trials market Medical Dialogues, August 24, 2025	Takeda eyes India for global clinical trials amid booming clinical trials market	India is a strategic growth market for Takeda, and we are making significant long-term investments... in terms of innovation and building capabilities, said Annapurna Das, the general manager of Takeda's India operations. Advertisement She did not share financial details of the investments.
26th August	GSK enters Indian oncology market with gynaecological cancer drugs The New Indian Express, August 26, 2025	GSK enters Indian oncology market with gynaecological cancer drugs	GlaxoSmithKline (GSK) on Monday announced its foray into the Indian oncology market with the launch of two precision therapies Jemperli (dostarlimab) and Zejula (niraparib) aimed at treating gynaecological cancers, one of the most common forms of cancer among women.
27th August	GSK Pharma reenters oncology market The Times of India, August 27, 2025	GSK Pharma reenters oncology market	GlaxoSmithKline Pharma is reentering the oncology market with the introduction of two advanced precision therapies for gynaecological cancer. The move signals GSK's renewed focus on building a foothold in India's cancer therapy and widening its innovative portfolio.
27th August	Takeda India develops new app to support patients with inflammatory bowel disease BioSpectrum India, August 27, 2025	Takeda India develops new app to support patients with inflammatory bowel disease	Takeda Biopharmaceuticals India has announced the launch of 'For You, With You IBD' (FYWY IBD), a mobile application designed to support individuals having Inflammatory Bowel Disease (IBD). Takeda's patient-centric strategy, the initiative is a digital health solution aimed at supporting everyday disease management and patient well-being.